昭和大学

腫瘍分子生物学研究所

Publications

業績

2012年度

原著論文

Fujita K, Sugiyama M, Akiyama Y, Hioki K, Kunishima M, Nishi K, Kobayashi M, Kawai K, Sasaki Y: N-Isopropyl-p-iodoamphetamine hydrochloride (IMP) is predominantly metabolized by CYP2C19. Drug Metab. Dispos., 40(5), 843-846 (2012). Sunakawa Y, Fujita K, Ichikawa W, Ishida H, Yamashita K, Araki K, Miwa K, Kawara K, Akiyama Y, Yamamoto W, Nagashima F, Saji S, Sasaki Y: A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1, *1/*6, or *1/*28. Oncology, 82(4), 242-248 (2012). Ando Y, Kawada K, Inada M, Morita S, Mitsuma A, Yasuda Y, Hiramatsu M, Fujimoto Y, Fujita K: Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured. Oncology, 83(1), 38-44 (2012). Hirose T, Murata Y, Oki Y, Sugiyama T, Kusumoto S, Ishida H, Shirai T, Nakashima M, Yamaoka T, Okuda K, Ohnishi T, Ohmori T: Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncol. Res., 20(2-3), 131-137 (2012). Okuda K, Hirose T, Oki Y, Murata Y, Kusumoto S, Sugiyama T, Ishida H, Shirai T, Nakashima M, Yamaoka T, Ohnishi T, Ohmori T: Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease. Anticancer Res., 32(12), 5475-5480 (2012). Sakai A, Kasahara K, Ohmori T, Kimura H, Sone T, Fujimura M, Nakao S: MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity. J. Thorac. Oncol., 7(9), 1337-1344 (2012).

総説

藤田健一:イリノテカン 最新の知見・臨床での実際 月刊薬事(The Pharmaceuticals Monthly),54(6), 79-82 (2012). 山岡利光, 大森亨 EGFR阻害剤の耐性とその克服 癌と化学療法 39( 6), 857-862 (2012).

著書

大森亨:薬剤耐性とその克服 新臨床腫瘍学(改訂第3版)(日本臨床腫瘍学会) 南江堂 pp.231-234 (2012).